; or (ii) was given priority review under section 515B. (e) Actions For purposes of expediting the development and review of in vitro clinical tests under this section, the Secretary may take the actions and additional actions set forth in section 515B(e) when reviewing such tests. Any reference or authorization in section 515B(e) with respect to a device shall be deemed a reference or authorization with respect to an in vitro clinical test for purposes of this section. (f) Guidance (1) In general Not later than one year after the date of enactment of the Verifying Accurate Leading-edge IVCT Development Act of 2020 , the Secretary shall issue draft guidance on the implementation of this section. Such guidance shall— (A) set forth the process by which a person may seek a designation under subsection (d); (B) provide a template for request under subsection (d); (C) identify the criteria the Secretary will use in evaluating a request for designation; and (D) identify the criteria and processes the Secretary will use to assign a team of staff, including team leaders, to review in vitro clinical tests designated for expedited development and priority review, including any training required for such personnel to ensure effective and efficient review. (2) Process Prior to finalizing the guidance under paragraph (1), the Secretary shall seek public comment on the draft guidance. The Secretary shall issue final guidance one year after the close of the comment period for the draft guidance. (g) Annual Report Unless otherwise specified by the Secretary, the requirements under section 587B(k) apply to in vitro clinical tests designated under this section. (h) Service of orders Orders of the Secretary under this section shall be served— (1) in person by any officer or employee of the Department of Health and Human Services designated by the Secretary